Book a Meeting

Non-Fucosylated Anti-Human Gastrin (XPA067. 06) Therapeutic Antibody (CAT#: BioBet-906ZP) Datasheet

Target
Gastrin
Isotype
IgG
Description
ADCC-Enhanced anti-Gastrin (XPA067.06) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Indication
Cancer
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Gastrin antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
GAST
Full Name
growth associated protein 43
Background
Gastrin is a hormone whose main function is to stimulate secretion of hydrochloric acid by the gastric mucosa, which results in gastrin formation inhibition. This hormone also acts as a mitogenic factor for gastrointestinal epithelial cells. Gastrin has two biologically active peptide forms, G34 and G17.
Alternative Names
GAST; gastrin; GAS; preprogastrin
Gene ID
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with GAST include Gastritis and Zollinger-Ellison Syndrome.
Related Pathways
Its related pathways are Secretion of Hydrochloric Acid in Parietal Cells and RET signaling.
Function
Gastrin stimulates the gastric mucosa to produce and secrete hydrochloric acid, and the pancreas secretes digestive enzymes. It can also stimulate smooth muscle contraction, increase blood circulation and water secretion in the stomach and intestines.
Post-translational modifications
Two different processing pathways probably exist in antral G-cells. In the dominant pathway progastrin is cleaved at three sites resulting in two major bioactive gastrins, gastrin-34 and gastrin-17. In the putative alternative pathway, progastrin may be processed only at the most C-terminal dibasic site resulting in the synthesis of gastrin-71. Sulfation enhances proteolytic processing, and blocks peptide degradation. Levels of sulfation differ between proteolytically-cleaved gastrins. Thus, gastrin-6 is almost 73% sulfated, whereas the larger gastrins are less than 50% sulfated. Sulfation levels are also tissue-specific.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
XPA067. 06
Host
Human
Species Reactivity
Human
Description
XPA067. 06 is an affinity matured, fully human anti-gastrin monoclonal antibody that was generated. The antibody was tested in a mouse gastric pH model to determine its effect on acid secretion. The results demonstrate that XPA067. 06 effectively binds and neutralizes human gastrin-17 in vivo with rapid onset and prolonged duration of efficacy.
Indication
Cancer

Cancer

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany